Nitrogen Attached Indirectly To The Hetero Ring By Nonionic Bonding Patents (Class 549/491)
-
Patent number: 10829441Abstract: Disclosed are ROS-sensitive NOS inhibitors, as well as methods of making and using the same.Type: GrantFiled: October 31, 2018Date of Patent: November 10, 2020Assignee: The University of ToledoInventors: Kevin M. Nash, Isaac Schiefer, Zahoor Shah
-
Patent number: 10364210Abstract: Provided herein are (phenylene)dialkanamines, and methods of producing such (phenylene)dialkanamines from various furanyl and benzyl compounds. Such furanyl compounds may include, for example, bis(nitroalkyl)furans, bis(aminoalkyl)furans, and nitroalkyl(furan)acetonitriles. Such compounds may include, for example, bis(nitroalkyl)benzenes. Provided herein are also alkyldiamines, and methods for producing such alkyldiamines from furanyl compounds.Type: GrantFiled: August 27, 2015Date of Patent: July 30, 2019Assignee: MICROMIDAS, INC.Inventors: Alex B. Wood, Makoto Nathanael Masuno, Ryan L. Smith, John Albert Bissell, II, Robert Joseph Araiza, Dimitri A. Hirsch-Weil
-
Patent number: 10188627Abstract: Provided herein are compounds of formula (I) useful for the treatment of PPAR-delta related diseases (e.g. mitochondrial diseases, muscular diseases, vascular diseases, demyelinating diseases and metabolic diseases).Type: GrantFiled: October 7, 2015Date of Patent: January 29, 2019Assignees: Mitobridge, Inc., Salk Institute for Biological StudiesInventors: Michael Downes, Ronald Evans, Arthur Kluge, Bharat Lagu, Masanori Miura, Sunil Kumar Panigrahi, Michael Patane, Susanta Samajdar, Ramesh Senaiar, Taisuke Takahashi
-
Publication number: 20150126511Abstract: The invention relates to novel cyclohexylamine derivatives and their use in the treatment and/or prevention of central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.Type: ApplicationFiled: September 30, 2014Publication date: May 7, 2015Inventors: Liming SHAO, Fengjiang WANG, Scott Christopher MALCOLM, Michael Charles HEWITT, Larry R. BUSH, Jianguo MA, Mark A. VARNEY, Una CAMPBELL, Sharon Rae ENGEL, Larry Wendell HARDY, Patrick KOCH, John E. CAMPBELL
-
Publication number: 20150080369Abstract: The present invention is directed to novel retinoid-related orphan receptor gamma (ROR?) modulators, processes for their preparation, pharmaceutical compositions containing these modulators, and their use in the treatment of inflammatory, metabolic and autoimmune diseases mediated by ROR?.Type: ApplicationFiled: April 25, 2013Publication date: March 19, 2015Inventors: Veronique Birault, Amanda Jennifer Campbell, Stephen Harrison, Joelle Le, Lena Shukla
-
Patent number: 8962865Abstract: A process is disclosed for the preparation of a compound of formula and/or an addition salt of a proton acid, wherein R1 and R2 independently represent alkyl, cycloalkyl, aryl or aralkyl, each aryl or aralkyl being optionally further substituted with alkyl, alkoxy and/or halogen.Type: GrantFiled: July 25, 2013Date of Patent: February 24, 2015Assignee: Lonza AGInventors: Dominique Michel, Rudolf Fuchs
-
Patent number: 8952094Abstract: A composition includes a reversible polymer material, which can reversibly transition between a liquid state and a solid state by reversible cycloaddition reactions, wherein upon cooling, the reversible polymer material transitions from a liquid state to a solid state by reversible cycloaddition reactions within a time period of less than about 10 seconds.Type: GrantFiled: May 30, 2013Date of Patent: February 10, 2015Assignee: Xerox CorporationInventors: James D. Mayo, Stephan Drappel, C. Geoffrey Allen, Biby E. Abraham, Sonja Hadzidedic
-
Patent number: 8927586Abstract: The present invention relates to novel TP receptor antagonists, which optionally cross the blood-brain barrier of a mammal. The invention also provides methods for treating a disorder related to activation of TP receptor utilizing the compounds of the invention.Type: GrantFiled: February 28, 2013Date of Patent: January 6, 2015Assignee: The Trustees of the University of PennsylvaniaInventors: John Q. Trojanowski, Virginia M. Y. Lee, Kurt R. Brunden, Amos B. Smith, Donna M. Huym, Carlo Ballatore, Anne-Marie Hogan, Francesco Piscitelli, Sugiyama Shimpei, Xiaozhao Wang
-
Publication number: 20140341986Abstract: Provided herein are methods for treating certain conditions, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a biguanide or related heterocyclic compound, e.g., metformin. Also provided herein are biguanide or related heterocyclic compound compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.Type: ApplicationFiled: August 4, 2014Publication date: November 20, 2014Inventors: Alain D. Baron, Mark S. Fineman, Nigel R.A. Beeley
-
Patent number: 8883180Abstract: The invention relates to active compound combinations, in particular a fungicidal and/or insecticidal composition, comprising Isotianil (3,4-dichloro-N-(2-cyanophenyl)-5-isothiazolecarboxamide) and at least one further insecticide of the anthranilamide group and optionally one further insecticide of the neonicotinoids. Moreover, the invention relates to a method for curatively or preventively controlling the phytopathogenic fungi and/or microorganisms and/or pests of plants or crops, to the use of a combination according to the invention for the treatment of seed, to a method for protecting a seed and not at least to the treated seed.Type: GrantFiled: August 29, 2013Date of Patent: November 11, 2014Assignee: Bayer Intellectual Property GmbHInventors: Lutz Assmann, Ulrike Wachendorff-Neumann, Peter Dahmen, Heike Hungenberg, Wolfgang Thielert
-
Publication number: 20140323501Abstract: Immune-modulators of formula (I) below are prepared: A pharmaceutical composition contains the immune-modulators. The pharmaceutical composition is used as a drug, especially as an immune-modulating drug. The compound can be used in treatment of immune disorders and for immune suppression. Thus, for example, the compound can be used in treating hypo-immunity, rejection after organ transplantation and auto-immune disease.Type: ApplicationFiled: July 5, 2012Publication date: October 30, 2014Applicant: INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCESInventors: Weijuan Han, Haijing Zhang, Xiaojian Wang, Jing Jin, Gang Li, Yi Zhang, Qiong Xiao, Wanqi Zhou, Xiaoguang Chen, Dali Yin
-
Publication number: 20140315898Abstract: The present invention relates to novel N-arylamide-substituted trifluoroethyl sulfide derivatives of the formula (I) in which X1, X2, X3, X4, R1, R2, R3, n have the meanings given in the description—to their use as acaricides and insecticides for controlling animal pests and to processes and intermediates for their preparationType: ApplicationFiled: December 12, 2012Publication date: October 23, 2014Applicant: BAYER CROPSCIENCE AGInventors: Adeline Koehler, Bernd Alig, Angela Becker, Arnd Voerste, Ulrich Goergens, Reiner Fischer, Wahed Ahmed Moradi, Silvia Cerezo-Galvez, Julia Johanna Hahn, Kerstin Ilg, Hans-Georg Schwarz, Takuya Gomibuchi, Masahito Ito, Daiei Yamazaki, Katsuhiko Shibuya, Eiichi Shimojo
-
Publication number: 20140275043Abstract: The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are substituted 3-phenylpropylamine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compositions are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.Type: ApplicationFiled: March 11, 2014Publication date: September 18, 2014Applicant: Acucela Inc.Inventors: Vladimir A. Kuksa, Mark W. Orme, Feng Hong, Ryo Kubota
-
Publication number: 20140275582Abstract: Provided herein are novel chiral sulfinamide and imine compounds. Also provided herein are methods of synthesizing novel chiral sulfinamide and imine compounds comprising simplified purification methods when compared to prior methods. The novel chiral sulfinamide and imine compounds are useful, for example, in the synthesis of complex natural products and pharmaceutical important compounds.Type: ApplicationFiled: March 12, 2014Publication date: September 18, 2014Applicants: Texas Tech University, Nanjing University, Institute of Chemistry and Biomedical SciencesInventor: Guigen LI
-
Publication number: 20140235533Abstract: The present invention provides compounds of formula I wherein Q is Q1 or Q2; A1, A2, A3 and A4 are independently of each other C—H, C—R7, or nitrogen; R1 is C1-C8haloalkyl; R2 is aryl or aryl substituted by one to five R11, or heteroaryl or heteroaryl substituted by one to five R11; and R3, R4, R5, R6 and R7 are as defined in the claims. The invention also provides methods of controlling insects, acarines, nematodes or molluscs which methods comprise applying to a pest, to a locus of a pest, or to a plant susceptible to attack by a pest an insecticidally, acaricidally, nematicidally or molluscicidally effective amount of a compound of formula (I).Type: ApplicationFiled: August 10, 2012Publication date: August 21, 2014Applicant: SYNGENTA PARTICIPATIONS AGInventors: Tomas Smejkai, Sebastian Volker Wendeborn, Jerome Yves Cassayre, Myriem El Qacemi, Bernhard Breit, Lisa Diab, Regis Jean Georges Mondiere
-
Patent number: 8716500Abstract: The present invention provides a method that allows production of stereospecific and asymmetrical five-membered ring-containing compounds serving as synthetic intermediates for formation of five-membered rings of prostaglandins and the like, with high yield and excellent stereoselectivity in terms of diastereoselectivity and enantioselectivity in a short process without requiring troublesome procedures such as optical resolution.Type: GrantFiled: April 27, 2012Date of Patent: May 6, 2014Assignee: Ono Pharmaceutical Co., Ltd.Inventor: Yujiro Hayashi
-
Publication number: 20140100371Abstract: A process for preparing azomethines of the general formula (V) where R is an optionally substituted carbocyclic aromatic radical having 6 to 24 carbon atoms or an optionally substituted alkyl radical or an optionally substituted heteroaromatic radical having 5 to 24 carbon atoms, and R1 is an optionally substituted carbocyclic aromatic radical having 6 to 24 carbon atoms or an optionally substituted heteroaromatic radical having 5 to 24 carbon atoms, R2 is hydrogen or an optionally substituted carbocyclic aromatic radical having 6 to 24 carbon atoms or an optionally substituted alkyl radical or an optionally substituted cycloalkyl radical N or an optionally substituted heteroaromatic radical having 5 to 24 carbon atoms by reacting alpha-oxo carboxylates of the general formula (I) where n is a number in the range from 1 to 6, M(n+) is a cation, with aryl bromides of the general formula (IV) and amines of the general formula (II) via the alpha-iminocarboxylate intermediate of the general formula (III), in the pType: ApplicationFiled: November 18, 2011Publication date: April 10, 2014Applicant: Saltigo GmbHInventors: Alain Cotte, Matthias Cotta, Felix Rudolph, Bingrui Song, Lukas Goossen
-
Patent number: 8669383Abstract: Described herein are single step methods of making various classes of alkylamine derivatives of furan and tetrahydrofuran by simultaneous contact of a sugar with H2, an acid catalyst and hydrogenation catalyst in the presence of an alkylamide solvent. The hydrogenation catalyst is a heterogeneous catalyst comprising a metal selected from the group consisting of Pt, Pd, and nickel. The acid catalysts may be homogeneous mineral acid or a heterogeneous acid catalyst on substrate. In a preferred practice the two catalysts are provided on a common heterogeneous bifunctional support. Using similar combinations of acid and hydrogenation catalysts, there is also described single step methods for making furandimethanol by simultaneously contacting a hexose with the two separate catalysts in the presence of H2 in an aprotic solvent, such as dimethylformamide.Type: GrantFiled: December 13, 2011Date of Patent: March 11, 2014Assignee: Archer Daniels Midland CompanyInventors: Stephen Howard, Alexandra Sanborn
-
Publication number: 20140051874Abstract: The present invention provides a method that allows production of stereospecific and asymmetrical five-membered ring-containing compounds serving as synthetic intermediates for formation of five-membered rings of prostaglandins and the like, with high yield and excellent stereoselectivity in terms of diastereoselectivity and enantioselectivity in a short process without requiring troublesome procedures such as optical resolution.Type: ApplicationFiled: April 27, 2012Publication date: February 20, 2014Applicant: ONO PHARMACEUTICAL CO., LTD.Inventor: Yujiro Hayashi
-
Patent number: 8653286Abstract: Methods for forming maleimide functionalized polymers are provided. In one such embodiment, a maleimide functionalized polymer is prepared in a method that includes a step of carrying out a reverse Diels-Alder reaction. Intermediates useful in the methods, as well as methods for preparing the intermediates, are also provided. Also provided are polymeric reagents, methods of using polymeric reagents, compounds and conjugates.Type: GrantFiled: August 7, 2012Date of Patent: February 18, 2014Assignee: Nektar TherapeuticsInventors: Samuel P. McManus, Antoni Kozlowski, Tracy L. Hutchison, Brian Bray, Xiaoming Shen
-
Patent number: 8614010Abstract: Provided are an organic electroluminescence device that not only provides high efficiency but also has a long lifetime, and an aromatic amine derivative that realizes the device. The organic electroluminescence device includes an aromatic amine derivative, including at least one substituent A having dibenzofuran and at least one substituent B selected from groups each having dibenzofuran or carbazole, in a molecule thereof, in which the substituent A and the substituent B include groups different from each other, and the substituent A and the substituent B are bonded to the same nitrogen atom, or different nitrogen atoms, in the molecule. The molecules of the aromatic amine derivative hardly crystallize, which improves a yield in the production of the organic electroluminescence device.Type: GrantFiled: November 24, 2009Date of Patent: December 24, 2013Assignee: Idemitsu Kosan, Co., Ltd.Inventors: Nobuhiro Yabunouchi, Masahiro Kawamura, Tomoki Kato
-
Publication number: 20130281462Abstract: Disclosed herein are compounds (for example, diamidine derivatives and prodrugs) and methods of use thereof, for example in treating muscular dystrophy (DM) or disease caused by a toxic RNA in a subject. In some embodiments, the methods include administering an effective amount of one of more of the disclosed compounds to a subject to treat or inhibit DM or a disease caused by or associated with toxic RNA, such as DM1, DM2, spinocerebellar ataxia type 8 (SCA8), fragile X tremor ataxia syndrome (FXTAS), or Huntington disease-like 2 (HLD2). In some examples, the methods include selecting a subject for treatment, for example selecting a subject with DM1, DM2, SCA8, FXTAS, or HLD2.Type: ApplicationFiled: April 19, 2013Publication date: October 24, 2013Applicants: University of OregonInventor: State of Oregon, acting by and through the State Board of Higher Education, on behalf of the University of Oregon
-
Publication number: 20130274283Abstract: Premature termination codons readthrough compounds, composition thereof, and methods of making and using the same are provided.Type: ApplicationFiled: February 11, 2013Publication date: October 17, 2013Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Richard A. GATTI, Liutao DU, Robert DAMOISEAUX, Chih-Hung LAI, Michael JUNG, Jin-Mo KU, Carmen BERTONI
-
Publication number: 20130252964Abstract: The present disclosure provides compounds, or pharmaceutically acceptable salts thereof, for killing or inhibiting the growth of a Candida or Aspergillus species or preventing or treating a mammal having candidiasis (oral and/or disseminated) or an Aspergillus infection.Type: ApplicationFiled: January 18, 2013Publication date: September 26, 2013Applicant: PolyMedix, Inc.Inventors: Richard W. Scott, Katie Freeman, Haizhong Tang, Gill Diamond
-
Patent number: 8513162Abstract: There is provided a halogen-containing organosulfur compound having a controlling effect on arthropod pests represented by the formula (I): wherein m represents 0, 1 or 2; n represents 0, 1 or 2; A represents an optionally substituted 3- to 8-membered saturated heterocyclic group; Q represents a fluorine atom or a C1-C5 haloalkyl group having at least one fluorine atom; R1, R1a and R3 independently represent an optionally halogenated C1-C4 chain hydrocarbon group, etc.; R2, R2a and R4 independently represent an optionally halogenated C1-C4 chain hydrocarbon group, etc.Type: GrantFiled: December 24, 2009Date of Patent: August 20, 2013Assignee: Sumitomo Chemical Company, LimitedInventor: Hiromasa Mitsudera
-
Publication number: 20130190370Abstract: The present invention relates to TP receptor antagonists, which have the ability to bind to TP receptor and optionally cross the blood brain barrier. The invention also provides compositions and methods for treating a disorder wherein activation of TP receptor is detrimental.Type: ApplicationFiled: July 27, 2011Publication date: July 25, 2013Applicant: The Trustees of the University of PennsylvaniaInventors: John Q. Trojanowski, Virginia M.Y. Lee, Kurt R. Brunden, Amos B. Smith, Donna M. Huryn, Carlo Ballatore, Anne-Marie Hogan, Francesco Piscitelli
-
Publication number: 20130109713Abstract: The invention provides a compound of formula I:or a salt thereof, wherein R3-R8 and X and Y have any of the values described in the specification, as well as compositions comprising a compound of formula I. The compounds are useful as antibacterial agents.Type: ApplicationFiled: June 24, 2011Publication date: May 2, 2013Inventors: Edmond J. Lavoie, Ajit Parhi, Daniel S. Pilch
-
Publication number: 20130095140Abstract: Provided herein are methods for treating certain conditions, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a biguanide or related heterocyclic compound, e.g., metformin. Also provided herein are biguanide or related heterocyclic compound compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.Type: ApplicationFiled: July 11, 2012Publication date: April 18, 2013Applicant: Elcelyx Therapeutics, Inc.Inventors: Alain D. Baron, Mark S. Fineman, Nigel R. A. Beeley
-
Patent number: 8357710Abstract: There is provided a compound of formula I, wherein R1a, R1b, X, Y1, Y2, Y3, Y4, Z1, Z2, R2 and R3 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful as selective agonists of the AT2 receptor, and thus, in particular, in the treatment of inter alia gastrointestinal conditions, such as dyspepsia, IBS and MOF, and cardiovascular disorders.Type: GrantFiled: April 12, 2006Date of Patent: January 22, 2013Assignee: Vicore Pharma ABInventors: Mathias Alterman, Anders Hallberg, Murugaiah Andappan Murugaiah Subbaiah
-
Publication number: 20120270902Abstract: The invention provides N-substituted benzenesulfonamides for use in treating or preventing cognitive disorders, such as Alzheimer's Disease. Compounds of particular interest are defined by Formula (I), wherein R1, R2, R3, R4, and R3?, are as described in the specification. The invention also encompasses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of treating cognitive disorders, including Alzheimer's disease using compounds of Formula (I).Type: ApplicationFiled: February 13, 2012Publication date: October 25, 2012Applicant: ELAN PHARMACEUTICALS, INC.Inventors: Martin Neitzel, Jennifer Marugg
-
Patent number: 8258324Abstract: Methods for forming maleimide functionalized polymers are provided. In one such embodiment, a maleimide functionalized polymer is prepared in a method that includes a step of carrying out a reverse Diels-Alder reaction. Intermediates useful in the methods, as well as methods for preparing the intermediates, are also provided. Also provided are polymeric reagents, methods of using polymeric reagents, compounds and conjugates.Type: GrantFiled: September 15, 2011Date of Patent: September 4, 2012Assignee: Nektar TherapeuticsInventors: Samuel P. McManus, Antoni Kozlowski, Tracy L. Hutchison, Brian Bray, Xiaoming Shen
-
Publication number: 20120220590Abstract: Compounds of formula (I) and pharmaceutical compositions containing them are described. The use of the compounds and compositions are also described.Type: ApplicationFiled: July 30, 2010Publication date: August 30, 2012Inventors: Pravin S. Thombare, Amitgiri Goswami, Edouard Zamaratski, Tomas Hansson, Thomas Norin
-
Publication number: 20120201958Abstract: The present invention is a plurality of metal-containing complexes of a multidentate ketoiminate.Type: ApplicationFiled: July 21, 2011Publication date: August 9, 2012Applicant: Air Products and Chemicals, Inc.Inventors: Xinjian Lei, Daniel P. Spence
-
Patent number: 8236972Abstract: The instant invention involves a process for enhancing molecular mass of biomass reactants. The process comprises first forming a substituted or unsubstituted furfural from a biomass. The substituted or unsubstituted furfural is then reacted with an activated methylene compound in the presence of a catalyst and, if desired, a solvent to form a Knoevenagel product. The product may then be hydrogenated to products containing an alcohol, ether, aldehyde, or ketone functional groups or to an olefinic or aliphatic species wherein as much as all of the oxygen and/or nitrogen has been removed.Type: GrantFiled: July 29, 2008Date of Patent: August 7, 2012Assignee: Georgia Tech Research CorporationInventors: Travis J. C. Hoskins, Carsten Sievers, Pradeep K. Agrawal, Christopher W. Jones
-
Publication number: 20120149693Abstract: The invention relates to protein binding interacting/binding compounds and methods of identifying and using them. The invention further relates to pharmaceutical compositions and methods for treating 5-HT2C and/or RSK disorders, including diseases and disorders mediated by GPCRs and/or RSKs.Type: ApplicationFiled: May 5, 2010Publication date: June 14, 2012Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.Inventor: Raymond G. Booth
-
Publication number: 20120095024Abstract: The present invention provides novel compounds that inhibit cell proliferation and cell division and that inhibit the activation of Hypoxia Inducible Factor (HIF)-mediated transcription and signaling under hypoxic conditions. In one aspect, the compounds of the present invention are useful for the preparation of a medicament for the treatment or prevention of a disease or disorder selected from the group consisting of an inflammatory disease, a hyperproliferative disease or disorder, a hypoxia-related pathology and a disease characterized by excessive vascularisation. Also provided is a pharmaceutical composition comprising a compound of the invention and a second therapeutic agent or radiation useful for the treatment or prevention of the mentioned diseases or disorders. In a first aspect the present invention relates to a compound having a structure according to formula (I).Type: ApplicationFiled: December 30, 2009Publication date: April 19, 2012Applicants: Elara Pharmaceuticals GmbH, European Molecular Biology Laboratory (EMBL)Inventors: Jorge Alonson, Arantxa Encionas Lopez, Marcel Muelbaler, Lochen Ammenn, Bernd Vendt, Joe Lewis, Christoph Schultes, Bernd Janssen
-
Publication number: 20120004225Abstract: The present invention provides bumetanide, furosemide, piretanide, azosemide, and torsemide analogs and compositions comprising such analogs. The present invention also provides pharmaceutical compositions containing these bumetanide, furosemide, piretanide, azosemide, and torsemide analogs and methods for their use. All of these analogs are particularly useful for the treatment and/or prophylaxis of conditions that involve the Na+K+Cl? co-transporter or GABAA receptor including but not limited to addictive disorders, Alzheimer's Disease, anxiety disorders, ascites, autism, bipolar disorder, cancer, depression, endothelial corneal dystrophy, edema, epilepsy, glaucoma, Huntington's Disease, insomnia, ischemia, migraine, migraine with aura, neuropathic pain, nociceptive neuralgia, nociceptive pain, ocular diseases, pain, Parkinson's disease, personality disorders, postherpetic neuralgia, psychosis, schizophrenia, seizure disorders, tinnitus, and withdrawal syndromes.Type: ApplicationFiled: January 22, 2010Publication date: January 5, 2012Applicant: NeuroTherapeutics Pharma, Inc.Inventors: Stephen Wanaski, John J. Partridge, Stephen D. Collins
-
Patent number: 8044222Abstract: The present invention provides a novel aromatic amine derivative having a specific structure and an organic electroluminescence device in which an organic thin film layer comprising a single layer or plural layers including at least a light emitting layer is interposed between a cathode and an anode, wherein at least one layer in the above organic thin film layer, particularly a hole transporting layer contains the aromatic amine derivative described above in the form of a single component or a mixed component. Use of the aromatic amine derivative described above materialize an organic electroluminescence device which reduces an operating voltage and makes molecules less liable to be crystallized and which enhances a yield in producing the organic EL device and has a long lifetime.Type: GrantFiled: August 6, 2007Date of Patent: October 25, 2011Assignee: Idemitsu Kosan Co., Ltd.Inventors: Nobuhiro Yabunouchi, Masahiro Kawamura, Hisayuki Kawamura
-
Publication number: 20110257226Abstract: There is provided a halogen-containing organosulfur compound having a controlling effect on arthropod pests represented by the formula (I): wherein m represents 0, 1 or 2; n represents 0, 1 or 2; A represents an optionally substituted 3- to 8-membered saturated heterocyclic group; Q represents a fluorine atom or a C1-C5 haloalkyl group having at least one fluorine atom; R1, R1a and R3 independently represent an optionally halogenated C1-C4 chain hydrocarbon group, etc.; R2, R2a and R4 independently represent an optionally halogenated C1-C4 chain hydrocarbon group, etc.Type: ApplicationFiled: December 24, 2009Publication date: October 20, 2011Inventor: Hiromasa Mitsudera
-
Publication number: 20110251196Abstract: The present disclosure is generally directed to compounds which can modulate G-protein coupled receptor 88, compositions comprising such compounds, and methods for modulating G-protein coupled receptor 88.Type: ApplicationFiled: October 5, 2010Publication date: October 13, 2011Inventors: Carolyn Diane Dzierba, Richard A. Hartz, Yingzhi Bi, Vijay T. Ahuja, Joanne J. Bronson, Kenneth Carson, Giovanni Cianchetta, Michael Green, David Kimball, S. Roy Kimura, Soojin Kwon, John E. Macor, Yulian Zhang, Greg Zipp
-
Patent number: 8017558Abstract: Novel carboxamides of the formula (I) The present application is further directed toward a plurality of processes for preparing these compounds and their use for controlling unwanted microorganisms, and also novel intermediates and their preparation.Type: GrantFiled: December 5, 2006Date of Patent: September 13, 2011Assignee: Bayer Cropscience AGInventors: Ralf Dunkel, Hans-Ludwig Elbe, Jörg Nico Greul, Herbert Gayer, Bernd-Wieland Krüger, Arnd Voerste, Ulrike Wachendorff-Neumann, Peter Dahmen
-
Patent number: 8013187Abstract: 2-cyclopenten-1-one oxime derivatives represented by Formula (I), or pharmaceutically acceptable salts thereof inhibit the production of TNF-? or PDE4, and therefore show therapeutic effect in inflammatory or immunological disorders mediated through TNF-? or PDE4.Type: GrantFiled: November 30, 2005Date of Patent: September 6, 2011Assignee: Amorepacific CorporationInventors: Yeonjoon Kim, Sun-Young Kim, Jung Sun Hwang, Kyoung Min Lim, Miyoung Park, Hyun Ju Koh, Sa-Yong Hong, Song Seok Shin, Jin Kyu Choi, Joo-Hyun Moh, Shin Chung, Byoung Young Woo, Sung Il Kim
-
Patent number: 7989497Abstract: The present invention relates to compounds of formula (I) wherein X, R1, R2, R3, R4 and R5 are as defined herein, which are useful for treating diseases which respond to CXCR2 receptor mediators. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.Type: GrantFiled: July 30, 2009Date of Patent: August 2, 2011Assignee: Novartis AGInventors: Urs Baettig, Anne-Marie D'Souza, Peter Hunt, Neil John Press, Simon James Watson
-
Patent number: 7977332Abstract: Certain noel N-(heteroarylalkyl)alkanediamine derivatives have provided unexpected insecticidal and acaricidal activity. These compounds are represented by formula I: wherein Ar, a, r, R, Ra, Rb, Rc, Rd, b, c, Re, Rf, Rg, Rh, R5, d, e, U, V, X, WR6 and R7 are fully described herein. In addition, compositions comprising an insecticidally effective amount of at least one compound of formula I, and optionally, an effective amount of at least one of a second compound, with at least one insecticidally compatible carrier are also disclosed; along with methods of controlling insects comprising applying said compositions to a locus where insects are present or are expected to be present.Type: GrantFiled: December 2, 2004Date of Patent: July 12, 2011Assignee: FMC CorporationInventors: David M. Roush, John F. Chiarello, Jianming Yu, Benjamin J. Dugan, George Theodoridis, Manorama M. Patel, Walter H. Yeager, Steven W. Szczepanski
-
Patent number: 7977496Abstract: Disclosed is an improved process for producing nitroguanidine derivatives represented by the formula (3), which has an insecticidal activity, or a salt thereof, wherein the substituents are defined herein, in which nitroisourea derivatives represented by the following general formula (1) or a salt thereof wherein the substituents are defined herein, and compounds represented by the following general formula (2) or a salt thereof, wherein the substituents are defined herein, are reacted in the presence of a base in an aqueous solution wherein an inorganic salt is dissolved at not less than 50% of its saturated solubility.Type: GrantFiled: February 7, 2007Date of Patent: July 12, 2011Assignee: Mitsui Chemicals, Inc.Inventors: Hisato Kamekawa, Tomotaka Miyashita, Hiroyuki Katsuta, Toshio Kitashima
-
Publication number: 20110165188Abstract: The present invention is directed to N-hydroxyamidino compounds which are modulators of indoleamine 2,3-dioxygenase (IDO), as well as compositions and pharmaceutical methods thereof.Type: ApplicationFiled: March 17, 2011Publication date: July 7, 2011Inventors: Andrew P. Combs, Brian M. Glass, Richard B. Sparks, Eddy Way Tsun Yue
-
ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS
Publication number: 20110152290Abstract: The present invention relates to compounds of the formula I, wherein A, Y, Z, R3 to R6, R20 to R22 and R50 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they are inhibitors of the endothelial differentiation gene receptor 2 (Edg-2, EDG2), which is activated by lysophosphatidic acid (LPA) and is also termed as LPA1 receptor, and are useful for the treatment of diseases such as atherosclerosis, myocardial infarction and heart failure, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.Type: ApplicationFiled: November 4, 2010Publication date: June 23, 2011Applicant: SANOFI-AVENTISInventors: Matthias SCHAEFER, Josef PERNERSTORFER, Dieter KADEREIT, Hartmut STROBEL, Werngard CZECHTIZKY, L. Charlie CHEN, Alena SAFAROVA, Aleksandra WEICHSEL, Marcel PATEK -
Publication number: 20110092539Abstract: The present invention relates to a heterocyclic derivative according to formula (I); wherein the variables are defined as in the specification, or to a pharmaceutically acceptable salt or solvate thereof. The present invention also relates to a pharmaceutical composition comprising said heterocyclic derivatives and to their use in therapy, for instance in the treatment or prevention of psychiatric diseases where an enhancement of synaptic responses mediated by AMPA receptors is required, including schizophrenia, depression and Alzheimer's disease.Type: ApplicationFiled: June 3, 2009Publication date: April 21, 2011Inventors: Jonathan Gillespie, Craig Jamieson, Zoran Rankovic
-
Patent number: 7902207Abstract: A process for producing an amine which is characterized by reacting an imine with a nucleophilic compound (except a trialkylsilyl vinyl ether) in the presence of a phosphoric acid derivative represented by the formula (1): wherein A1 represents a spacer; X1 and X2 represent each independently a divalent nonmetal atom or a divalent nonmetal atomic group; and Y1 is oxygen or sulfur. The invention provides a process by which amines (particularly optically active amines) useful as intermediates of medicines, agricultural chemicals, or the like can be produced without special post-treatment in high yield at high optical purity; and phosphoric acid derivatives (particularly optically active phosphoric acid derivatives) useful in the production of the amines.Type: GrantFiled: January 26, 2005Date of Patent: March 8, 2011Assignee: Takasago International CorporationInventors: Masahiro Terada, Daisuke Uraguchi, Keiichi Sorimachi, Hideo Shimizu
-
Publication number: 20100324159Abstract: Embodiments of the present invention are directed to porous resins for solid phase extractions. The resins feature at least one hydrophobic component, at least one hydrophilic component and at least one ion exchange functional group. The resins exhibit superior wetting and ion exchange performance.Type: ApplicationFiled: August 12, 2010Publication date: December 23, 2010Applicant: Waters Technologies CorporationInventors: Peter Jeng Jong LEE, John E. O'Gara